AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05232708
Drug: Semaglutide B, 1.34 mg/mL
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subjects will receive single dose of 0.5 mg Semaglutide B, 1.34 mg/mL subcutaneously.
Trial: NCT05232708
Drug: Semaglutide D, 1.0 mg/mL
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subjects will receive single dose of 0.5 mg Semaglutide D, 1.0 mg/mL subcutaneously.
Trial: NCT06461208
Drug: Encapsulated FMT
RxNorm normalized name: poly (lactide-co-glycolide)-polyethylene glycol nanoparticles encapsulating quercetin
DrugBank: Quercetin (DB04216)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Encapsulated Faecal Microbiota Transplant
Trial: NCT06021977
Drug: Zanubrutinib
RxNorm normalized name: Zanubrutinib
DrugBank: Zanubrutinib (DB15035)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zanubrutinib was specifically designed to deliver complete and sustained inhibition of the BTK protein by optimizing bioavailability, half-life, and selectivity.
Trial: NCT04911959
Drug: Lenvatinib
RxNorm normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenvatinib is taken orally.
Trial: NCT01787136
Drug: Dextromethorphan
RxNorm normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: added on therapy
Trial: NCT04867317
Drug: Somatropin
RxNorm normalized name: Somatropin
DrugBank: Somatotropin (DB00052)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants (n=172) will be randomized in a 1:1 ratio to rhGH (n=86) versus placebo (n=86) for six months, stratified by participating site. Both study participants and the study team will be blinded to treatment assignment. All participants will complete in-clinic follow-ups at Days 14, 40, 65, and 90 (3 months) and at day 180 (6 months). The primary outcome will be the mean difference in QoL-AGHDA scores between treatment arms at 6 months follow-up. Patients will discontinue the study intervention at 6 months, and will be followed-up two weeks subsequent, in order to assure patient safety and wellness, and to ensure maximal facilitation of patient transition back into routine care.
Trial: NCT05635708
Drug: Tislelizumab
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by intravenous infusion
Trial: NCT05635708
Drug: BGB-A445
RxNorm normalized name: BGB-DXP593
DrugBank: BGB-DXP593 (DB16357)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by intravenous infusion
Trial: NCT05635708
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Investigator's choice; administered by intravenous infusion
Trial: NCT05635708
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Investigator's choice; administered by intravenous infusion
Trial: NCT05635708
Drug: pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Investigator's choice; administered by intravenous infusion
Trial: NCT05635708
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Investigator's choice; administered by intravenous infusion
Trial: NCT05635708
Drug: Nab paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Investigator's choice; administered by intravenous infusion
Trial: NCT05635708
Drug: BGB-15025
RxNorm normalized name: BGB-DXP593
DrugBank: BGB-DXP593 (DB16357)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered Orally
Trial: NCT04788823
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment groups will be administered different dosages of Prednisone post vasectomy reversal.
Trial: NCT06701136
Drug: Sudapyridine
RxNorm normalized name: Sudapyridine
DrugBank: Sudapyridine (DB18984)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In Study A, Cycle 1 (D1-D10): Participants will take Sudapyridine (WX-081) 300 mg once daily after breakfast. Cycle 2 (D11-D14): Participants will take Sudapyridine 300 mg once daily after breakfast with itraconazole 200 mg daily; an additional itraconazole dose (200 mg) will be given after dinner on D11. In Study B, Cycle 1 (D1): Participants will take Sudapyridine 450 mg as a single dose after breakfast. Cycle 2 (D22): Participants will take Sudapyridine 450 mg with rifampin 600 mg daily (D15-D27). In Study C, Cycle 1 (D1): Sudapyridine 450 mg will be given fasting; Cycle 2 (D15): after a high-fat breakfast.
Trial: NCT06701136
Drug: Itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In Study A: Participants will receive itraconazole capsules at 200 mg orally once daily after breakfast during Cycle 2 (D11-D14). An additional dose of itraconazole (200 mg) will be administered after dinner on D11.
Trial: NCT06701136
Drug: Rifampin
RxNorm normalized name: Rifampin
DrugBank: Rifampin (DB01045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In Study B: Participants will receive rifampin capsules at 600 mg orally once daily under fasting conditions during Cycle 2 (D15-D27).
Trial: NCT06712875
Drug: Trametinib and Nivolumab
RxNorm normalized name: nivolumab and relatlimab
DrugBank: Trametinib (DB08911)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Trametinib combined with nivolumab (Cohort A)
Trial: NCT06712875
Drug: Dabrafenib, trametinib, nivolumab
DrugBank: Trametinib (DB08911)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dabrafenib + trametinib combined with nivolumab (Cohort B)
Trial: NCT06121843
Drug: BMS-986393
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT06121843
Drug: Alnuctamab
RxNorm normalized name: Alnuctamab
DrugBank: Alnuctamab (DB17194)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT06121843
Drug: Mezigdomide
RxNorm normalized name: Mezigdomide
DrugBank: Mezigdomide (DB17584)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT04851457
Drug: Intravenous tirofiban combination therapy
DrugBank: Tirofiban (DB00775)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will enter the tirofiban treatment protocol immediately within half an hour after randomization and prior to the femoral artery puncture. Tirofiban is administered as an intravenous bolus dose of 10 μg/kg injection within 3 min and then by an intravenous infusion at a rate of 0.1 μg/(kg·min) for 24 hours.
Trial: NCT04619927
Drug: Normal metabolisers and unknown metaboliser state
RxNorm normalized name: cytarabine and daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Clopidogrel 75mg once daily
Trial: NCT06121843
Drug: Iberdomide
RxNorm normalized name: Iberdomide
DrugBank: Iberdomide (DB12101)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT04442412
Drug: Vitamin D3 (Cholecalciferol)
RxNorm normalized name: vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients in the Experimental arm (Arm B) will receive also a prephase therapy with VitD and a supplementation of VitD during the intere period of immunochemotherapy according to a prefixed schedule. Choice of type of immunochemotherapy will not rely on Comprehensive Geriatric Assessment (CGA) result, but treatment at reduced doses with R-miniCHOP is highly recommended option for UNFIT and FRAIL patients.
Trial: NCT04901676
Drug: Leronlimab
RxNorm normalized name: Leronlimab
DrugBank: Leronlimab (DB05941)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leronlimab 700 mg (first dose) followed by weekly 350 mg
Trial: NCT06159062
Drug: 162
RxNorm normalized name: R1626
DrugBank: R1626 (DB05060)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The investigational product 162 is a novel monoclonal antibody targeting HBsAg.
Trial: NCT05106517
Drug: Denosumab
RxNorm normalized name: Denosumab
DrugBank: Denosumab (DB06643)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Denosumab 60mg/6 months subcutaneously + placebo iv
Trial: NCT05530356
Drug: Aminohippurate Sodium Inj 20%
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)
Trial: NCT05530356
Drug: Iohexol Inj 300 MG/ML
DrugBank: Iohexol (DB01362)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diagnostic aid/agent used to measure glomerular filtration rate (GFR)
Trial: NCT05530356
Drug: Dextran 40
RxNorm normalized name: Dextran 40
DrugBank: Dextran (DB09255)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diagnostic aid/agent used to measure glomerular size selectivity
Trial: NCT04905342
Drug: NVP-1805
RxNorm normalized name: NVP
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: orally, once daily on Period 1 and Period 3 (or Period 2 and Period 4) (NVP-1805 80/10/20.8mg)
Trial: NCT04905342
Drug: NVP-1805-R1and NVP-1805-R2
RxNorm normalized name: NVP
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: orally, once daily on Period 1 or Period 3 (or Period 2 and Period 4) (NVP-1805-R1 80mg, NVP-1805-R2 10/20.8mg)
Trial: NCT06557902
Drug: Lumateperone 10.5 mg capsule
DrugBank: Lumateperone (DB06077)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lumateperone 10.5 mg capsule, oral administration
Trial: NCT06557902
Drug: Lumateperone 21 mg capsule
RxNorm normalized name: lumateperone
DrugBank: Lumateperone (DB06077)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lumateperone 21 mg capsule, oral administration
Trial: NCT06557902
Drug: Lumateperone 5 mg ODT
RxNorm normalized name: lumateperone 10.5 MG
DrugBank: Lumateperone (DB06077)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lumateperone 5 mg ODT, oral administration
Trial: NCT06557902
Drug: Lumateperone 10.5 mg ODT
DrugBank: Lumateperone (DB06077)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lumateperone 10.5 mg ODT, oral administration
Trial: NCT06557902
Drug: Lumateperone 15.5 mg ODT
DrugBank: Lumateperone (DB06077)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lumateperone 5 mg ODT + 10.5 mg ODT, oral administration
Trial: NCT06557902
Drug: Lumateperone 21 mg ODT
RxNorm normalized name: lumateperone 21 MG
DrugBank: Lumateperone (DB06077)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lumateperone 21 mg ODT, oral administration
Trial: NCT00003536
Drug: antineoplaston A10
RxNorm normalized name: Antineoplaston A10
DrugBank: Antineoplaston A10 (DB11702)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04721756
Drug: 18F-LY3546117 Injection
RxNorm normalized name: (18F)-Fluoride
DrugBank: Fluoride ion F-18 (DB09398)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 370 megabecquerel (MBq) intravenous injection
Trial: NCT05767723
Drug: Monotherapy: Ticagrelor alone OR Prasugrel alone
DrugBank: Prasugrel (DB06209)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ticagrelor alone (90 mg twice daily) OR Prasugrel alone (10 mg once daily)
Trial: NCT06272409
Drug: Desloratadine 0.5 MG/ML
RxNorm normalized name: desloratadine 0.5 MG/ML
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Desloratadine oral solution
Trial: NCT06382519
Drug: Thalidomide
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: thalidomide, dose 1.5-2.5mg/kg.d, orally taken before bedtime.
Trial: NCT04594811
Drug: NT-I7
RxNorm normalized name: NT-I7
DrugBank: Efineptakin alfa (DB16395)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by intramuscular (IM) injection.
Trial: NCT04594811
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered by intravenous (IV) injection.
Trial: NCT06134492
Drug: Acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dosage: 10mg/kg (current) body weight every 8 hours, dose adjustment to renal function according to technical information.~Mode of administration: intravenous (i.v.)
Trial: NCT05265325
Drug: epoetin alfa, darbepoetin alfa, Mircera®, or their biosimilars
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose regimen and adjustment rules according to the USPI or SmPC or local practice
Trial: NCT05802212
Drug: Metformin intervention for 12 weeks
RxNorm normalized name: alogliptin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: PCOS patients were treated with metformin orally for 12 weeks, and various indicators related to fertility were observed.
Trial: NCT05531383
Drug: Memantine Hydrochloride
RxNorm normalized name: Memantine Hydrochloride
DrugBank: Memantine (DB01043)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: study the effect of memantine on platelet, platelet/lymphocyte ratio (PLR) and C reactive protein (CRP) \& serum NSE levels in patients with moderate to severe TBI as well as their outcome.
Trial: NCT06285448
Drug: Lecanemab
RxNorm normalized name: Lecanemab
DrugBank: Lecanemab (DB14580)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bi-weekly infusions of lecanemab \[exposure\].
Trial: NCT06228326
Drug: Pembrolizumab (KEYTRUDA®)
RxNorm normalized name: pembrolizumab Injection [Keytruda]
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: PD-1 immune checkpoint inhibitor
Trial: NCT04693533
Drug: Fremanezumab Prefilled Syringe [Ajovy]
RxNorm normalized name: fremanezumab Prefilled Syringe [Ajovy]
DrugBank: Fremanezumab (DB14041)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The treatment is 225 mg (dissolved in 1.5 ml saline) fremanezumab. Fremanezumab (Ajovy) is a month-long-acting anti-CGRP injection that patients are taught to self-administer at home.
Trial: NCT05491226
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab 200 mg is administered intravenously at Week 1, then every 3 weeks during the treatment period (6 weeks). Therapy will continue for until initiation of SOC curative-intent treatment (neoadjuvant chemo therapy or surgery) at Week 7.
Trial: NCT05491226
Drug: Axatilimab
RxNorm normalized name: Axatilimab
DrugBank: Axatilimab (DB16388)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Axatilimab 1 mg/kg is administered intravenously weekly starting 1 week post- RT (Week 3). Therapy will continue until initiation of SOC curative-intent treatment (neoadjuvant chemo therapy or surgery) at Week 7.
Trial: NCT06387147
Drug: Metronidazole
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Métronidazole 500mg 3 times per day during 14 days oral route or nasogastric tube or jejunostomy tube (in the case of an ostomy)
Trial: NCT06153173
Drug: Mirdametinib
RxNorm normalized name: Mirdametinib
DrugBank: Mirdametinib (DB07101)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirdametinib is administered at a dose of 2 mg/m2, twice a day (BID) with a maximum dose of 4 mg BID on a continuous daily schedule. Consecutive doses should be separated by minimum 6 hours and maximum 14 hours.
Trial: NCT05444699
Drug: Sugar syrup
RxNorm normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral suspension administered the same amount in milliliters as experimental product once a day for three days
Trial: NCT06094556
Drug: SHR-1826
RxNorm normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dose is calculated based on the subjects' baseline weight.
Trial: NCT06024746
Drug: Finerenone
RxNorm normalized name: Finerenone
DrugBank: Finerenone (DB16165)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral finerenone.
Trial: NCT06024746
Drug: Empagliflozin
RxNorm normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral empagliflozin.
Trial: NCT06066437
Drug: Arm B: 177Lu rhPSMA-10.1 plus Degarelix
DrugBank: Degarelix (DB06699)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive 177Lu rhPSMA-10.1 alone. Participants will receive 177Lu rhPSMA-10.1 with Degarelix
Trial: NCT06045884
Drug: Ropivacaine injection
RxNorm normalized name: ROPivacaine Injection
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After general anesthesia, patients will be injected 20ml ropivacaine around femoral nerve.
Trial: NCT06045884
Drug: Saline injection
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After general anesthesia, patients will be injected 20ml 0.9% saline around femoral nerve.
Trial: NCT06555497
Drug: clobetasol propionate 0.05% ointment
DrugBank: Clobetasol propionate (DB01013)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: clobetasol propionate 0.05% ointment
Trial: NCT05773183
Drug: GnRH
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 men in OBS2 planned for GnRH analogue therapy will undergo data collection prior, and 3 months post initiation of GnRH analogue therapy
Trial: NCT00225550
Drug: ADH -1 (Exherin™)
RxNorm normalized name: ADH-1
DrugBank: ADH-1 (DB05485)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05608356
Drug: Sham Injection
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
DrugBank: Bean (DB14709)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham injection as a placebo injection
Trial: NCT06346392
Drug: Ramucirumab+ paclitaxel
RxNorm normalized name: Ramucirumab
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ramucirumab 8 mg/kg IV on Days 1 and 15 and paclitaxel 80 mg/m2 IV on Days 1, 8, and 15, Q4W
Trial: NCT06346392
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 80 mg/m2 IV on Days 1, 8, and 15, Q4W (for participants with contraindication to ramucirumab only)
Trial: NCT06346392
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 75-100 mg/m2 IV on Day 1, Q3W (for participants with contraindication to ramucirumab only)
Trial: NCT06346392
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Irinotecan 150-180 mg/m2 IV on Days 1 and 15, Q4W
Trial: NCT06346392
Drug: TAS-102
RxNorm normalized name: TAS-102
DrugBank: TAS-102 (DB08937)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAS-102 35 mg/m2 up to a maximum of 80 mg orally twice a day on Days 1 to 5 and Days 8 to 12, Q4W (except China)
Trial: NCT06346392
Drug: Apatinib
RxNorm normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib 500-850 mg at Investigator's discretion based on participant's condition and tolerability, orally once daily, Q4W (China only)
Trial: NCT06556446
Drug: Tenecteplase and Alteplase
RxNorm normalized name: Tenecteplase
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The timepoints, dose, and type of IVT will be collected as well as any complications occuring.
Trial: NCT05521698
Drug: Apalutamide
RxNorm normalized name: Apalutamide
DrugBank: Apalutamide (DB11901)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT06480383
Drug: ITI-1284 10 mg
RxNorm normalized name: Arthur Itis
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ITI-1284 10 mg tablet, taken once daily, sublingual administration.
Trial: NCT06480383
Drug: ITI-1284 20 mg
RxNorm normalized name: Arthur Itis
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ITI-1284 20 mg tablet, taken once daily, sublingual administration.
Trial: NCT05823532
Drug: Infliximab
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab has FDA approval for the treatment of rheumatoid arthritis and inflammatory bowel syndrome. The current proposal represents the use of infliximab as an experimental tool to dissect the role of inflammatory processes leading to changes in brain reward circuitry and changes in specific symptom domains.~Double-blinded infusions of infliximab will be administered in the GCTSA Clinical Research Center, located at Emory University Hospital. Independent pharmacists will dispense either infliximab or placebo in a 250ml saline bag according to a computer-generated randomization list provided by the study pharmacist.
Trial: NCT05528458
Drug: Osimertinib 80Mg Tab
RxNorm normalized name: OSIMERTINIB 80MG TAB
DrugBank: Osimertinib (DB09330)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subjects have a osimertinib (80 mg, orally, once daily) to suppress the progression of remaining GGN(s) in other lobes following surgical resection
Trial: NCT06192784
Drug: Lenvatinib plus pucotenlimab
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: lenvatinib (8mg, qd) plus pucotenlimab (200mg, q3w)
Trial: NCT06166589
Drug: Zimberelimab
RxNorm normalized name: Zimberelimab
DrugBank: Zimberelimab (DB17505)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zimberelimab, 240mg, day1. Every 3 weeks as a cycle.
Trial: NCT06166589
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxaliplatin 60mg/m2, day1、day8. Every 3 weeks as a cycle.
Trial: NCT06166589
Drug: S-1
RxNorm normalized name: LIS-1
DrugBank: Tegafur (DB09256)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: S-1(BSA \< 1.2m2, 40 mg/day; BSA = 1.2\~1.4 m2, 60 mg/day; BSA = 1.4\~1.6 m2, 80 mg/day; BSA \> 1.6 m2, 100 mg/day; bid, day1-14). Every 3 weeks as a cycle.
Trial: NCT06166589
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Irinotecan, 130 mg/m2, day 1, day 8. Every 3 weeks as a cycle.